The effect of the PI side chain on the binding of optimized carboxylate and activated carbonyl inhibitors of the hepatitis C virus NS3 protease

被引:1
作者
Kawai, Stephen H. [2 ]
LaPlante, Steven R. [1 ]
Llinas-Brunet, Montse [1 ]
Hucke, Oliver [1 ]
机构
[1] Boehringer Ingelheim Canada Ltd, Dept Chem, Laval, PQ H7S 2G5, Canada
[2] KLIE, Montreal, PQ, Canada
关键词
PEPTIDE-BASED INHIBITORS; SERINE-PROTEASE; CRYSTALLOGRAPHIC ANALYSIS; CRYSTAL-STRUCTURE; POTENT; DESIGN; RESOLUTION; ELASTASE; CHYMOTRYPSIN; PROTEINASE;
D O I
10.4155/FMC.10.198
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Peptidyl inhibitors of the hepatitis C virus NS3 protease hold much promise as direct-acting antiviral agents against hepatitis C infection. The optimization of N-terminal cleavage products, found to exhibit activity (product inhibition) against the enzyme, has led to potent tripeptide inhibitors that bear free C-terminal carboxylate groups. An analogous activated carbonyl compound (pentafluoroethyl ketone) bearing a PI norvaline (Nva) was found to possess comparable activity against hepatitis C virus protease. However, an analogue bearing an aminocyclopropylcarboxylic acid (Acca) PI residue exhibited very poor activity. F-19-NMR studies indicate that the propensity of the Acca-derived activated carbonyl to form hemiketals is only slightly reduced compared with that of a PI Nva equivalent. These results, as well as molecular modeling studies, argue against steric hindrance of the nucleophilic attack of Ser-139 accounting for the poor mechanism-based inhibition by the former. We hypothesize that the conformational properties of the respective C-termini in the context of an adaptable active site account for the divergent PI structure activity relationships.
引用
收藏
页码:1073 / 1081
页数:9
相关论文
共 50 条
  • [31] Inhibitors of hepatitis C virus NS3/4A: α-Ketoamide based macrocyclic inhibitors
    Avolio, Salvatore
    Robertson, Keith
    Hernando, Jose Ignacio Martin
    DiMuzio, Jillian
    Summa, Vincenzo
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (08) : 2295 - 2298
  • [32] The index of ideality of correlation: QSAR studies of hepatitis C virus NS3/4A protease inhibitors using SMILES descriptors
    Ghiasi, T.
    Ahmadi, S.
    Ahmadi, E.
    Talei Bavil Olyai, M. R.
    Khodadadi, Z.
    SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2021, 32 (06) : 495 - 520
  • [33] Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative Behavior
    Rajagopalan, Ravi
    Misialck, Shawn
    Stevens, Sarah K.
    Myszka, David G.
    Brandhuber, Barbara J.
    Ballard, Joshua A.
    Andrews, Steven W.
    Seiwert, Scott D.
    Kossen, Karl
    BIOCHEMISTRY, 2009, 48 (11) : 2559 - 2568
  • [34] Discovery of a Potent and Selective Noncovalent Linear Inhibitor of the Hepatitis C Virus NS3 Protease (BI 201335)
    Llinas-Brunet, Montse
    Bailey, Murray D.
    Goudreau, Nathalie
    Bhardwaj, Punit K.
    Bordeleau, Josee
    Boes, Michael
    Bousquet, Yves
    Cordingley, Michael G.
    Duan, Jiamin
    Forgione, Pat
    Garneau, Michel
    Ghiro, Elise
    Gorys, Vida
    Goulet, Sylvie
    Halmos, Ted
    Kawai, Stephen H.
    Naud, Julie
    Poupart, Marc-Andre
    White, Peter W.
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (17) : 6466 - 6476
  • [35] Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity
    Bachmetov, L.
    Gal-Tanamy, M.
    Shapira, A.
    Vorobeychik, M.
    Giterman-Galam, T.
    Sathiyamoorthy, P.
    Golan-Goldhirsh, A.
    Benhar, I.
    Tur-Kaspa, R.
    Zemel, R.
    JOURNAL OF VIRAL HEPATITIS, 2012, 19 (02) : E81 - E88
  • [36] The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A protease
    Monteagudo, E.
    Fonsi, M.
    Chu, X.
    Bleasby, K.
    Evers, R.
    Pucci, V.
    Orsale, M. V.
    Cianetti, S.
    Ferrara, M.
    Harper, S.
    Laufer, R.
    Rowley, M.
    Summa, V.
    XENOBIOTICA, 2010, 40 (12) : 826 - 839
  • [37] Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
    McPhee, Fiona
    Sheaffer, Amy K.
    Friborg, Jacques
    Hernandez, Dennis
    Falk, Paul
    Zhai, Guangzhi
    Levine, Steven
    Chaniewski, Susan
    Yu, Fei
    Barry, Diana
    Chen, Chaoqun
    Lee, Min S.
    Mosure, Kathy
    Sun, Li-Qiang
    Sinz, Michael
    Meanwell, Nicholas A.
    Colonno, Richard J.
    Knipe, Jay
    Scola, Paul
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (10) : 5387 - 5396
  • [38] Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle
    McGivern, David R.
    Masaki, Takahiro
    Lovell, William
    Hamlett, Chris
    Saalau-Bethell, Susanne
    Grahamc, Brent
    JOURNAL OF VIROLOGY, 2015, 89 (10) : 5362 - 5370
  • [39] Human pegivirus (GB virus C) NS3 protease activity inhibits induction of the type I interferon response and is not inhibited by HCV NS3 protease inhibitors
    Chowdhury, Adnan Y.
    Tavis, John E.
    George, Sarah L.
    VIROLOGY, 2014, 456 : 300 - 309
  • [40] Phosphonate inhibitors of West Nile virus NS2B/NS3 protease
    Skorenski, Marcin
    Milewska, Aleksandra
    Pyrc, Krzysztof
    Sienczyk, Marcin
    Oleksyszyn, Jozef
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2019, 34 (01) : 8 - 14